Abstract 1879P
Background
Cancer affects many aspects of life and can have negative consequences such as reducedː health and quality of life and mental disorders. Cancer patients face most of the stressors associated with diagnosis and treatment. The aim of this study is investigating the effect of family support on the mental health of patients with breast Cancer.
Methods
This cross-sectional study examined 70 breast cancer patients who were referred within 6 months to Imam Khomeini and Shohadah Ha* Tir Hospitals for radiotherapy, chemotherapy or follow- up treatment. In terms of mental health, these patients were assessed using the criteria of hospital anxiety and depression and distress thermometer, and the level of family support using the McMaster Family Assessment Device and attachment style criteria. The psychiatric interview with the patients was conducted by the psychiatric resident and all questionnaires were completed by her in face-to-face interviews or video calls with the patient. Before the start of the study, all patients gave written informed consent. The Family Support Questionnaire contains 60 questions that identify the structural, professional, and interactive characteristics of the family. This questionnaire has 7 subscales.
Results
The mean (standard deviation) of the total score on the Family Support Questionnaire for the subjects studied was 15.7 (2.96) with a range of 9.87 to 21.06. the mean (standard deviation) of anxiety and depression scores were 9.68 (5.34) and 8.34 (4.41), respectively. the results show that increasing the score on anxiety and depression significantly increases family support and its sub-comparisons.
Conclusions
The study revealed that the mean scores of the depression and anxiety in breast cancer patients is more than normal limitation. The results showed that decreasing family support and its sub- comparisons (an increase in the score indicates an unhealthy situation) significantly increases anxiety and depression in these individuals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Iran University of Medical Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05